Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial.
Akihiro OhbaChigusa MorizaneYasuyuki KawamotoYoshito KomatsuMakoto UenoSatoshi KobayashiMasafumi IkedaMitsuhito SasakiJunji FuruseNaohiro OkanoNobuyoshi HiraokaHiroshi YoshidaAya KuchibaRyo SadachiKenichi NakamuraNaoko MatsuiYoshiaki NakamuraWataru OkamotoTakayuki YoshinoTakuji OkusakaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
T-DXd showed promising activity in patients with HER2-positive BTC and a signal of efficacy in patients with HER2-low BTC. Although the safety profile was generally manageable, ILD requires careful monitoring and early intervention.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- papillary thyroid
- randomized controlled trial
- interstitial lung disease
- squamous cell
- induced pluripotent stem cells
- pluripotent stem cells
- cross sectional
- open label
- systemic sclerosis
- rheumatoid arthritis
- study protocol
- placebo controlled